
    
      This is a follow-up protocol to prospectively monitor pregnancy, delivery, and neonatal
      outcomes of all women who were treated with corifollitropin alfa and became pregnant during
      the base Trial 38833. For this follow-up trial (38834), no investigational products will be
      administered and no study specific assessments are required, but information will be obtained
      as per standard clinical practice.
    
  